Characterization of Salmonella spp. mutants with reduced fluoroquinolone susceptibility:: Importance of efflux pump mechanisms

被引:17
作者
Cebrián, L [1 ]
Rodríquez, JC [1 ]
Escribano, I [1 ]
Royo, G [1 ]
机构
[1] Univ Miguel Hernandez, Hosp Gen Univ Elche, Elche, Spain
关键词
Salmonella mutants; fluoroquinolones; pump efflux;
D O I
10.1159/000084417
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We studied the importance of the efflux pump mechanisms in Salmonella spp. mutants with reduced fluoroquinolone susceptibility generated in vitro. Methods: The efflux pump was studied using MC-207,110 as an inhibitor of these systems. Results: Wild strains with mutations in gyrA exhibit greater activity of the efflux pump systems than nalidixic-acid-susceptible strains (30-fold). When we evaluate the respective mutants, in those of susceptible strains there is seen to be greater elimination of the antibiotic (13-fold), whereas in mutants of nalidixic-acid-resistant strains these systems are not modified. When evaluating the influence of the antibiotic generating the mutants, ciprofloxacin is seen to be the quinolone that activates the efflux pump systems the most. Conclusions: Repeated exposure to low concentrations of all the fluoroquinolones studied leads to activation of the efflux pump systems and a reduction in susceptibility, even when there are no mutations in gyrA. Activation of these mechanisms is greatly influenced by the chemical structure of the antibiotic. The capacity of these systems to eliminate fluoroquinolones is limited and therefore, for the microorganism to acquire high-level fluoroquinolone resistance, they must be complemented by other mechanisms. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 20 条
[1]   Is it time to change fluoroquinolone breakpoints for Salmonella spp.? [J].
Aarestrup, FM ;
Wiuff, C ;
Molbak, K ;
Threlfall, EJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :827-829
[2]   The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204 [J].
Baucheron, S ;
Imberechts, H ;
Chaslus-Dancla, E ;
Cloeckaert, A .
MICROBIAL DRUG RESISTANCE, 2002, 8 (04) :281-289
[3]   Killing of gram-negative bacteria by ciprofloxacin within both healthy human neutrophils and neutrophils with inactivated O2-dependent bactericidal mechamisms [J].
Cantón, E ;
Peman, J ;
Cabrera, E ;
Velert, M ;
Orero, A ;
Pastor, A ;
Gobernado, M .
CHEMOTHERAPY, 1999, 45 (04) :268-276
[4]   Characterisation of Salmonella spp. mutants produced by exposure to various fluoroquinolones [J].
Cebrian, L ;
Sirvent, E ;
Díaz, JCR ;
Ruiz, M ;
Royo, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (02) :134-139
[5]   Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field [J].
Giraud, E ;
Brisabois, A ;
Martel, JL ;
Chaslus-Dancla, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2131-2137
[6]   Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar typhimurium [J].
Giraud, E ;
Cloeckaert, A ;
Kerboeuf, D ;
Chaslus-Dancla, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) :1223-1228
[7]   Quinolones in gastrointestinal infections [J].
Graninger, W ;
ZedtwitzLiebenstein, K ;
Laferl, H ;
Burgmann, H .
CHEMOTHERAPY, 1996, 42 :43-53
[8]   Topoisomerase IV mutations in quinolone-resistant salmonellae selected in vitro [J].
Hansen, H ;
Heisig, P .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 2003, 9 (01) :25-32
[9]   Comparison of gyrA mutations, cyclohexane resistance, and the presence of class I integrons in Salmonella enterica from farm animals in England and Wales [J].
Liebana, E ;
Clouting, C ;
Cassar, CA ;
Randall, LP ;
Walker, RA ;
Threlfall, EJ ;
Clifton-Hadley, FA ;
Ridley, AM .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) :1481-1486
[10]   The French antibiotic resistance monitoring programs [J].
Martel, JL ;
Tardy, F ;
Brisabois, A ;
Lailler, R ;
Coudert, M ;
Chaslus-Dancla, E .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (04) :275-283